SBIR Phase I: Consortium for High Throughput CubeLab by Space Tango

SBIR 第一阶段：Space Tango 高通量 CubeLab 联盟

• 批准号: 2416101
• 负责人: Twyman Clements
• 金额: $ 27.49万
• 依托单位: SPACE TANGO LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-03-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2416101&HistoricalAwards=false
• 关键词: SBIR; Phase; Consortium; Throughput; CubeLab

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to address some of the most impactful health research questions by using high throughput techniques in the weightless environment of Low Earth Orbit (LEO). When studying diseases or developing treatments on Earth, cellular models are often used to “stand in” for humans during the development phase because of the high number of trials that can be performed in a short period of time. The microgravity environment offered in LEO, provides a unique laboratory where some diseases can be studied more efficiently than on the ground. This project’s technology is being developed to allow for an unprecedented number of samples to be studied in space, and making world-class health research finally achievable by providing the statistical significance that could only be achieved on Earth. The consortium being formed brings us together with a group of world-class researchers in fields such as cancer research and drug delivery. Beyond potential health impacts, these studies will encourage the small businesses involved to develop products and strategies for the future, both on Earth and in space.This Small Business Innovation Research (SBIR) Phase I project will double the current capacity of a biological platform technology to enable nearly 600 individual samples in one payload. All samples will be hosted in an environmentally-controlled, sealed system, matching the best incubation conditions available on Earth, and flown in space during this Phase I project for 30 days on the International Space Station (ISS). This high throughput system will allow for numerous start-ups and labs, including collaborators from Notre Dame, the University of San Diego, Mithrilome, Encapsulate, Massachusetts General Hospital, and Mount Sinai Icahn School of Medicine. These collaborators will fly specialized cells, groups of cells, and nanomaterials to screen for the best candidates in which to target further translational research and commercialization efforts. Enough statistical evidence will be gathered to match the quality of any ground-based study that could be carried out. The members of the consortium will carry out research related to Rett syndrome, Alzheimer’s disease, biomanufacturing of health-related products, drug delivery formulations, brain cancer, gastrointestinal cancer therapies, and the heart.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是通过在近地轨道 (LEO) 失重环境中研究疾病或研究时使用高通量技术来解决一些最具影响力的健康研究问题。在地球上开发治疗方法时，细胞模型通常在开发阶段用来“代替”人类，因为可以在短时间内进行大量试验，低地球轨道提供的微重力环境提供了一个独特的实验室。有些疾病可能发生在哪里该项目的技术正在开发中，以允许在太空中研究数量空前的样本，并通过提供只能在地球上实现的统计显着性，最终实现世界级的健康研究。正在组建的联盟将我们与癌症研究和药物输送等领域的世界级研究人员聚集在一起，除了潜在的健康影响之外，这些研究还将鼓励参与的小企业为地球的未来开发产品和战略。以及太空中的小型企业创新研究(SBIR) 第一阶段项目将使生物平台技术的现有容量增加一倍，以便在一个有效载荷中容纳近 600 个单独的样本。所有样本都将存放在一个环境控制的密封系统中，以匹配地球上现有的最佳孵化条件，并且在第一阶段项目中，该系统将在国际空间站 (ISS) 上进行为期 30 天的太空飞行，这一高通量系统将为众多初创企业和实验室提供支持，其中包括来自圣母大学、圣地亚哥大学、Mithrilome 的合作者。 Encapsulate、马萨诸塞州总医院和西奈山伊坎医学院将利用专门的细胞、细胞群和纳米材料来筛选最佳候选者，以收集足够的统计证据，以开展进一步的转化研究和商业化工作。为了与任何可以进行的地面研究的质量相匹配，该联盟的成员将开展与雷特综合症、阿尔茨海默病、健康相关产品的生物制造、药物输送配方、大脑相关的研究。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力价值和更广泛的影响审查标准进行评估，被认为值得支持。